Aerie Pharmaceuticals Completes Promising Phase 3 Study on Dry Eye Treatment

Aerie Pharmaceuticals Inc ((AERI)) announced an update on their ongoing clinical study.

Aerie Pharmaceuticals Inc. recently completed a Phase 3 study titled ‘A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-3).’ The study aimed to assess the safety and effectiveness of AR-15512 in treating dry eye disease, a condition affecting millions globally. This research is significant as it could lead to a new treatment option for patients suffering from this common eye condition.

The study tested AR-15512, an ophthalmic solution designed to modulate cold thermoreceptors in the eye, potentially increasing tear production and alleviating symptoms of dry eye disease. The treatment involved administering one drop of 0.003% AR-15512 or a placebo vehicle in each eye twice daily for 90 days.

This interventional study was randomized and double-masked, meaning neither the participants nor the investigators knew who received the actual treatment or placebo. The primary purpose was treatment, with the main goal being to evaluate the increase in tear production.

The study began on July 18, 2022, with primary completion anticipated by June 2, 2025, and the last update submitted on July 22, 2025. These dates are crucial as they mark the progress and expected timeline for results dissemination.

The completion of this study could positively impact Aerie Pharmaceuticals’ stock performance, especially if the results demonstrate significant efficacy. This could enhance investor sentiment and position the company favorably against competitors in the ophthalmic treatment market. Aerie Pharmaceuticals was acquired by Alcon in November 2022, which may further influence market dynamics.

The study is now completed, with further details available on the ClinicalTrials portal.